-
Barclays Shares Its Thoughts On Gilead Sciences Post-Earnings
Wednesday, July 27, 2016 - 9:12am | 379Read More...Barclays remains Overweight on Gilead Sciences, Inc. (NASDAQ: GILD) on valuation and franchise stability, despite reporting disappointing second-quarter results on the heels of hepatitis C drug Harvoni's continued sales declines. Harvoni, Sovaldi Sales for Harvoni plunged about 29 percent to $2.56...
-
Baird: Gilead Set For Q1 EPS Miss, But Hep C Trends Still Good Long Term
Tuesday, April 12, 2016 - 10:06am | 368Read More...The first quarter earnings of Gilead Sciences, Inc. (NASDAQ: GILD) may miss the Street view, but promising Hep C Rx trends drive a positive outlook, according to a note from Baird. Analyst Brian Skorney said, "Our estimate for pro forma fully diluted EPS is $2.92 versus consensus at $3.12. We think...
-
Gilead Sciences: Here's What A Bull And A Bear Are Saying
Wednesday, July 29, 2015 - 10:34am | 483Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading higher by more than 4 percent Wednesday after the company reported better-than-expected earnings for its second quarter. Here are opposing views of what two of Wall Street's top analysts are saying. Bank Of America: Long-Term...
-
Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says
Tuesday, April 21, 2015 - 12:57pm | 346Read More...In a report published Tuesday, RBC Capital Markets analyst Michael Yee commented on the increasing Street "appreciation" over the idea that Gilead Sciences, Inc. (NASDAQ: GILD) should acquire Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Yee noted that many investors are working...
